

SCHEDULE OF PHARMACEUTICAL BENEFITS EFFECTIVE 1 MARCH 2013

ERRATA

(1) This Erratum corrects the entry in the 1 March 2013 PBS Schedule for Pregabalin. The entry should appear as follows:

PBS Item Code	Name, Restriction, Manner of Administration and Form	Max Qty (Packs)	No. of Rpts	Premium	Dispensed Price for Max Quantity	Maximum Recordable Value for Safety Net	Brand Name	Manufacturer
	<p>PREGABALIN <u>Authority required (STREAMLINED)</u> 4172 Neuropathic pain The Clinical criteria is: The condition must be refractory to treatment with other drugs. <u>Note</u> Continuing Therapy Only For prescribing by nurse practitioners as continuing therapy only, where the treatment of, and prescribing of medicine for, a patient has been initiated by a medical practitioner. Further information can be found in the Explanatory Notes for Nurse Practitioners.</p>							
2348N NP	pregabalin 25 mg capsule, 56	1	5	..	26.20	27.31	Lyrica	PF
2335X NP	pregabalin 75 mg capsule, 56	1	5	..	48.87	36.10	Lyrica	PF
2355Y NP	pregabalin 150 mg capsule, 56	1	5	..	70.39	36.10	Lyrica	PF
2363J NP	pregabalin 300 mg capsule, 56	1	5	..	101.81	36.10	Lyrica	PF

(2) This Erratum corrects the entry in the 1 March 2013 PBS Schedule for Nicorette and Nicabate P nicotine transdermal patches (item codes 9198D and 5465P). The Schedule entry should appear as shown below:

PBS Item Code	Name, Restriction, Manner of Administration and Form	Max Qty (Packs)	No. of Rpts	Premium	Dispensed Price for Max Quantity	Maximum Recordable Value for Safety Net	Brand Name	Manufacturer
	<p>NICOTINE <u>Authority required</u> Nicotine dependence in an Aboriginal or a Torres Strait Islander person as the sole PBS-subsidised therapy</p> <p><u>Note</u> Only 2 courses of PBS-subsidised nicotine replacement therapy will be authorised per year. No applications for increased maximum quantities and/or repeats will be authorised. Benefit is improved if used in conjunction with a comprehensive support and counselling program.</p> <p><u>Authority required</u> Short-term sole PBS-subsidised therapy as an aid to achieving abstinence in a patient who has indicated they are ready to cease smoking and who has entered a comprehensive support and counselling program. Details of the program must be specified in the initial authority application</p> <p><u>Note</u> A maximum of 12 weeks of PBS-subsidised nicotine replacement therapy will be authorised per year. No applications for increased maximum quantities and/or repeats will be authorised.</p> <p><u>Authority required</u> Short-term sole PBS-subsidised therapy as an aid to achieving abstinence in a patient who has indicated they are ready to cease smoking and who is entering a comprehensive support and counselling program during the consultation at which this authority is requested. Details of the program must be specified in the initial authority application</p> <p><u>Note</u> A maximum of 12 weeks of PBS-subsidised nicotine replacement therapy will be authorised per year. No applications for increased maximum quantities and/or repeats will be authorised.</p>							
9198D NP	NICOTINE Transdermal patch releasing approximately 15 mg per 16 hours, 28	1	2	..	55.32	36.10	Nicorette Patch	JT
5465P NP	nicotine 21 mg/24 hours patch, 28	1	2	..	55.32	36.10	Nicabate P	GC

(3) This Erratum corrects the entry in the 1 March 2013 Schedule for Olanzapine.

The following Note should appear in the Schedule entry for all Olanzapine items. The Note was omitted for items 1024X, 1037N, 1041T, 1042W, 3381Y, 3382B, 3384D, and 3385E.

Note

Shared Care Model:

For prescribing by nurse practitioners where care of a patient is shared between a nurse practitioner and medical practitioner in a formalised arrangement with an agreed management plan. Further information can be found in the Explanatory Notes for Nurse Practitioners.

(4) This Erratum corrects the entry in the 1 March 2013 Schedule for Tocilizumab.

The Notes with the heading “TREATMENT OF ADULT PATIENTS WITH SEVERE ACTIVE RHEUMATOID ARTHRITIS” and with the subheadings:

- (1) How to prescribe PBS-subsidised bDMARD therapy after 1 August 2010.
- (2) Swapping therapy.
- (3) Baseline measurements to determine response.

are not relevant to the section 100 Highly Specialised Drugs listing of Tocilizumab for systemic juvenile idiopathic arthritis. These Notes do not apply to the PBS availability of items 1423X, 1464C, 1419Q, 1481Y, 1482B and 1476Q.